This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by van Ogtrop, M. L.
Right arrow Articles by Vesga, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Ogtrop, M. L.
Right arrow Articles by Vesga, O.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2000, p. 943-949, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative Bacteria

M. L. van Ogtrop,1,2,* D. Andes,3,4 T. J. Stamstad,3 B. Conklin,3 W. J. Weiss,5 W. A. Craig,3,4 and O. Vesga3,4

Leiden University Medical Centre, Leiden,1 and Rotterdam University Hospital, Rotterdam,2 The Netherlands; Veterans Affairs Hospital3 and University of Wisconsin,4 Madison, Wisconsin; and Wyeth-Ayerst Research, Pearl River, New York5

Received 8 March 1999/Returned for modification 18 September 1999/Accepted 10 January 2000

The in vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) were assessed in an experimental murine thigh infection model in neutropenic mice. Mice were infected with one of several strains of Streptococcus pneumoniae, Staphylococcus aureus, Escherichia coli, or Klebsiella pneumoniae. Most infections were treated with a twice-daily dosing schedule, with administration of 0.75 to 192 mg of GAR-936 or WAY 152,288 per kg of body weight. A maximum-effect dose-response model was used to calculate the dose that produced a net bacteriostatic effect over 24 h of therapy. This dose was called the bacteriostatic dose. More extensive dosing studies were performed with S. pneumoniae 1199, E. coli ATCC 25922, and K. pneumoniae ATCC 43816, with doses being given as one, two, four, or eight equal doses over a period of 24 h. The dosing schedules were designed in order to minimize the interrelationship between the various pharmacokinetic and pharmacodynamic parameters studied. These parameters were time above 0.03 to 32 times the MIC, area under the concentration-time curve (AUC), and maximum concentration of drug in serum (Cmax). The bacteriostatic dose remained essentially the same, irrespective of the dosing frequency, for S. pneumoniae 1199 (0.3 to 0.9 mg/kg/day). For E. coli ATCC 25922 and K. pneumoniae ATCC 43816, however, more frequent dosing led to lower bacteriostatic doses. Pharmacokinetic studies demonstrated dose-dependent elimination half-lives of 1.05 to 2.34 and 1.65 to 3.36 h and serum protein bindings of 59 and 71% for GAR-936 and WAY 152,288, respectively. GAR-936 and WAY 152,288 were similarly effective against the microorganisms studied, with small differences in maximum effect and 50% effective dose. The glycylcyclines were also similarly effective against tetracycline-sensitive and tetracycline-resistant bacteria. Time above a certain factor (range, 0.5 to 4 times) of the MIC was a better predictor of in vivo efficacy than Cmax or AUC for most organism-drug combinations. The results demonstrate that in order to achieve 80% maximum efficacy, the concentration of unbound drug in serum should be maintained above the MIC for at least 50% of the time for GAR-936 and for at least 75% of the time for WAY 152,288. The results of these experiments will aid in the rational design of dose-finding studies for these glycylcyclines in humans.

* Corresponding author. Mailing address: Department of Medical Microbiology and Infectious Diseases, University Hospital Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands. Phone: -31-10-4633510. Fax: -31-10-4633875. E-mail: vanogtrop{at}bacl.azr.nl.

Antimicrobial Agents and Chemotherapy, April 2000, p. 943-949, Vol. 44, No. 4
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A. (2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother 64: 824-828 [Abstract] [Full Text]  
  • Vaudaux, P., Fleury, B., Gjinovci, A., Huggler, E., Tangomo-Bento, M., Lew, D. P. (2009). Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 3150-3152 [Abstract] [Full Text]  
  • Nicasio, A. M., Crandon, J. L., Nicolau, D. P. (2009). In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates. Antimicrob. Agents Chemother. 53: 2756-2761 [Abstract] [Full Text]  
  • Salvatore, C. M., Techasaensiri, C., Tagliabue, C., Katz, K., Leos, N., Gomez, A. M., McCracken, G. H., Hardy, R. D. (2009). Tigecycline Therapy Significantly Reduces the Concentrations of Inflammatory Pulmonary Cytokines and Chemokines in a Murine Model of Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 53: 1546-1551 [Abstract] [Full Text]  
  • Crandon, J. L., Banevicius, M. A., Nicolau, D. P. (2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother. 53: 1165-1169 [Abstract] [Full Text]  
  • Pankuch, G. A., Appelbaum, P. C. (2009). Postantibiotic Effect of Tigecycline against 14 Gram-Positive Organisms. Antimicrob. Agents Chemother. 53: 782-784 [Abstract] [Full Text]  
  • Bowker, K. E., Noel, A. R., MacGowan, A. P. (2008). Pharmacodynamics of Minocycline against Staphylococcus aureus in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 52: 4370-4373 [Abstract] [Full Text]  
  • Kelesidis, T., Karageorgopoulos, D. E., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 62: 895-904 [Abstract] [Full Text]  
  • Passarell, J. A., Meagher, A. K., Liolios, K., Cirincione, B. B., Van Wart, S. A., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2008). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections. Antimicrob. Agents Chemother. 52: 204-210 [Abstract] [Full Text]  
  • Meagher, A. K., Passarell, J. A., Cirincione, B. B., Van Wart, S. A., Liolios, K., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections. Antimicrob. Agents Chemother. 51: 1939-1945 [Abstract] [Full Text]  
  • Slover, C. M, Rodvold, K. A, Danziger, L. H (2007). Tigecycline: A Novel Broad-Spectrum Antimicrobial. The Annals of Pharmacotherapy 41: 965-972 [Abstract] [Full Text]  
  • Scheetz, M. H., Qi, C., Warren, J. R., Postelnick, M. J., Zembower, T., Obias, A., Noskin, G. A. (2007). In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626 [Abstract] [Full Text]  
  • Peleg, A. Y., Potoski, B. A., Rea, R., Adams, J., Sethi, J., Capitano, B., Husain, S., Kwak, E. J., Bhat, S. V., Paterson, D. L. (2007). Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59: 128-131 [Abstract] [Full Text]  
  • Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., Ellis-Grosse, E. J. (2006). Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58: 1221-1229 [Abstract] [Full Text]  
  • Scheetz, M. H, Reddy, P., Nicolau, D. P, Noskin, G. A, Postelnick, M. J, Stosor, V., Zembower, T. R (2006). Peritoneal Fluid Penetration of Tigecycline. The Annals of Pharmacotherapy 40: 2064-2067 [Abstract] [Full Text]  
  • Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265 [Abstract] [Full Text]  
  • Scheetz, M. H., Hurt, K. M., Noskin, G. A., Oliphant, C. M. (2006). Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens.. Am J Health Syst Pharm 63: 1346-1360 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Ong, C. T., Babalola, C. P., Nightingale, C. H., Nicolau, D. P. (2005). Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 56: 498-501 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Muralidharan, G., Fruncillo, R. J., Micalizzi, M., Raible, D. G., Troy, S. M. (2005). Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects. Antimicrob. Agents Chemother. 49: 1656-1659 [Abstract] [Full Text]  
  • Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. (2005). Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects. Antimicrob. Agents Chemother. 49: 220-229 [Abstract] [Full Text]  
  • Betriu, C., Culebras, E., Rodriguez-Avial, I., Gomez, M., Sanchez, B. A., Picazo, J. J. (2004). In Vitro Activities of Tigecycline against Erythromycin-Resistant Streptococcus pyogenes and Streptococcus agalactiae: Mechanisms of Macrolide and Tetracycline Resistance. Antimicrob. Agents Chemother. 48: 323-325 [Abstract] [Full Text]  
  • Lefort, A., Lafaurie, M., Massias, L., Petegnief, Y., Saleh-Mghir, A., Muller-Serieys, C., Le Guludec, D., Fantin, B. (2003). Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis. Antimicrob. Agents Chemother. 47: 216-222 [Abstract] [Full Text]  
  • Milatovic, D., Schmitz, F.-J., Verhoef, J., Fluit, A. C. (2003). Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial Isolates. Antimicrob. Agents Chemother. 47: 400-404 [Abstract] [Full Text]  
  • Wallace, R. J. Jr., Brown-Elliott, B. A., Crist, C. J., Mann, L., Wilson, R. W. (2002). Comparison of the In Vitro Activity of the Glycylcycline Tigecycline (Formerly GAR-936) with Those of Tetracycline, Minocycline, and Doxycycline against Isolates of Nontuberculous Mycobacteria. Antimicrob. Agents Chemother. 46: 3164-3167 [Abstract] [Full Text]  
  • Chanawong, A., M'Zali, F. H., Heritage, J., Lulitanond, A., Hawkey, P. M. (2001). SHV-12, SHV-5, SHV-2a and VEB-1 extended-spectrum {beta}-lactamases in Gram-negative bacteria isolated in a university hospital in Thailand. J Antimicrob Chemother 48: 839-852 [Abstract] [Full Text]  
  • Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y., Tyrrell, K. (2000). Comparative In Vitro Activities of GAR-936 against Aerobic and Anaerobic Animal and Human Bite Wound Pathogens. Antimicrob. Agents Chemother. 44: 2747-2751 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»